StockData
Bone Biologics Corp logo

Bone Biologics Corp (BBLG) stock

BBLGNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 6/30
$0.29−0.02 (-5.92%)

Close on Nov 18, 2026Market cap $986.22KP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$986.22K
P/E ratio
–
Price to sales
–
Price to book
0.17
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$2.84M
EPS, diluted
-$2.65
Book value per share
$1.59
Diluted shares
4M

Trading

Previous close
$0.31
Open
$0.32
Day's range
$0.28 – $0.32
Volume
39,418
Average volume (20 days)
459,838
52-week range
$0.27 – $2.39
RSI (14 days)
33.7
Volatility (1 year)
70.1%
Relative volume
0.11×

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodBBLGS&P 500DifferenceBBLG per yearS&P 500 per year
1 month-26.3%-4.3%−22.0 pts
3 months-54.8%-4.6%−50.1 pts
Year to date-79.9%+7.9%−87.8 pts
1 year-82.1%+11.8%−94.0 pts
3 years-99.0%+68.0%−167.0 pts-78.5%+18.9%
5 years-100.0%+66.2%−166.2 pts-85.8%+10.7%

Fifteen years at a glance

Fiscal years 2010 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$3.01M

Net income

-$2.84M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Bone Biologics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Bone Biologics

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration in spinal fusion surgery. Its core technology platform utilizes NELL-1, a proprietary recombinant human protein growth factor designed to regulate skeletal tissue formation and stem cell differentiation. The company's lead product candidate is NB1, a combination medical device that incorporates the NELL-1 recombinant protein with demineralized bone matrix (DBM). The product is designed to promote targeted bone growth during spinal fusion procedures, initially targeting adult patients with degenerative disc disease undergoing transforaminal lumbar interbody fusion. Beyond spinal applications, the company holds rights to develop the platform for osteoporosis and trauma treatments.

Company profile, executives and history

Bone Biologics stock: common questions

What is Bone Biologics's stock price?

BBLG closed at $0.29 on Nov 18, 2026, down 5.92% on the day. Over the past 52 weeks it traded between $0.27 and $2.39.

What is Bone Biologics's market cap?

Bone Biologics was worth $986.22K at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is BBLG's P/E ratio?

Bone Biologics lost money over fiscal 2025 (diluted EPS -$2.65), so it has no meaningful P/E ratio.

Does Bone Biologics pay a dividend?

No. Bone Biologics has not paid a cash dividend over the last twelve months.

How has BBLG stock performed over the past year?

Including dividends, BBLG returned -82.1% over the past year, against +11.8% for the S&P 500.

How many BBLG shares are sold short?

0M shares were sold short at the latest FINRA report, 0.52% of the float, or 1.0 days of average trading volume.

Who are Bone Biologics's competitors?

Companies most similar to Bone Biologics by business, industry and size include SMTI, RGNT, OPHI, OFIX, LFWD.

See a number that looks wrong?